Millennium Management
AKBA icon

Millennium Management’s Akebia Therapeutics AKBA Stock Holding History

Millennium Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-700,000
Closed -$503K – 6918
2022
Q1 		$503K Buy
+700,000
New +$1.5M ﹤0.01% 5117
2021
Q1 		– Sell
-600,000
Closed -$1.68M – 5855
2020
Q4 		$1.68M Buy
+600,000
New +$1.75M ﹤0.01% 3381

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management's AKBA Position: Q2 2026 in Review

Millennium Management increased its Akebia Therapeutics (AKBA) stake by 34% in Q2 2026, buying an estimated $967K and bringing the position to 3,196,605 shares worth $3.64M. The position accounts for ﹤0.01% of the portfolio, ranked #3301.

Millennium Management first reported a position in AKBA in Q3 2014 and has held it in 45 quarters since. The position peaked at $15.4M in Q3 2017. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Millennium Management held 3,196,605 shares of Akebia Therapeutics worth $3.64M as of Q2 2026.
  • Millennium Management bought 811,892 Akebia Therapeutics shares in Q2 2026, an estimated $967K.
  • Akebia Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q2 2026, its #3301 holding.
  • Millennium Management first reported a position in Akebia Therapeutics in Q3 2014 and has held it in 45 quarters since.
  • Millennium Management's Akebia Therapeutics position peaked at $15.4M in Q3 2017.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.